JP2011528895A5 - - Google Patents

Download PDF

Info

Publication number
JP2011528895A5
JP2011528895A5 JP2011519185A JP2011519185A JP2011528895A5 JP 2011528895 A5 JP2011528895 A5 JP 2011528895A5 JP 2011519185 A JP2011519185 A JP 2011519185A JP 2011519185 A JP2011519185 A JP 2011519185A JP 2011528895 A5 JP2011528895 A5 JP 2011528895A5
Authority
JP
Japan
Prior art keywords
protein sequence
prevention
rv3616c protein
treatment
latent tuberculosis
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2011519185A
Other languages
English (en)
Japanese (ja)
Other versions
JP2011528895A (ja
JP5873332B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2009/059580 external-priority patent/WO2010010177A1/en
Publication of JP2011528895A publication Critical patent/JP2011528895A/ja
Publication of JP2011528895A5 publication Critical patent/JP2011528895A5/ja
Application granted granted Critical
Publication of JP5873332B2 publication Critical patent/JP5873332B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2011519185A 2008-07-25 2009-07-24 新規化合物および方法 Expired - Fee Related JP5873332B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US8372008P 2008-07-25 2008-07-25
US61/083,720 2008-07-25
PCT/EP2009/059580 WO2010010177A1 (en) 2008-07-25 2009-07-24 Novel compositions and methods

Publications (3)

Publication Number Publication Date
JP2011528895A JP2011528895A (ja) 2011-12-01
JP2011528895A5 true JP2011528895A5 (enExample) 2012-09-06
JP5873332B2 JP5873332B2 (ja) 2016-03-01

Family

ID=41217660

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2011519185A Expired - Fee Related JP5873332B2 (ja) 2008-07-25 2009-07-24 新規化合物および方法

Country Status (24)

Country Link
US (2) US20110117119A1 (enExample)
EP (1) EP2315773B1 (enExample)
JP (1) JP5873332B2 (enExample)
KR (1) KR20110044883A (enExample)
CN (1) CN102164952B (enExample)
AU (1) AU2009273130B2 (enExample)
BR (1) BRPI0916703A2 (enExample)
CA (1) CA2731499C (enExample)
CO (1) CO6341637A2 (enExample)
CY (1) CY1118200T1 (enExample)
DK (1) DK2315773T3 (enExample)
EA (1) EA024826B1 (enExample)
ES (1) ES2602430T3 (enExample)
HR (1) HRP20161458T1 (enExample)
HU (1) HUE031044T2 (enExample)
IL (1) IL210559A0 (enExample)
LT (1) LT2315773T (enExample)
MX (1) MX2011000983A (enExample)
PL (1) PL2315773T3 (enExample)
PT (1) PT2315773T (enExample)
SG (1) SG192456A1 (enExample)
SI (1) SI2315773T1 (enExample)
UA (1) UA107330C2 (enExample)
WO (1) WO2010010177A1 (enExample)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE445638T1 (de) * 1998-11-04 2009-10-15 Isis Innovation Tuberkulose diagnose test
PL2315834T3 (pl) 2008-07-25 2018-12-31 Glaxosmithkline Biologicals S.A. Białko rv2386c związane z gruźlicą, jego kompozycje i zastosowania
WO2010010180A1 (en) * 2008-07-25 2010-01-28 Glaxosmithkline Biologicals S.A. Novel compositions and methods
EP2156945A1 (en) 2008-08-13 2010-02-24 Novelis Inc. Clad automotive sheet product
DK2421557T3 (en) 2009-04-24 2019-03-25 Statens Seruminstitut TB TUBERCULOSE VACCINE FOR PREVENTION PREVENTION
AU2011209399B2 (en) 2010-01-27 2014-04-10 Glaxo Group Limited Modified tuberculosis antigens
CA2923755C (en) 2013-09-27 2023-03-14 Codexis, Inc. Automated screening of enzyme variants
CA2923758C (en) * 2013-09-27 2022-08-30 Codexis, Inc. Structure based predictive modeling
GB201405921D0 (en) * 2014-04-02 2014-05-14 Glaxosmithkline Biolog Sa Novel methods for inducing an immune response
CN106546737A (zh) * 2016-10-24 2017-03-29 广州迪澳医疗科技有限公司 一种体外检测活动性结核的方法
GB201621686D0 (en) 2016-12-20 2017-02-01 Glaxosmithkline Biologicals Sa Novel methods for inducing an immune response
GB201707700D0 (en) 2017-05-12 2017-06-28 Glaxosmithkline Biologicals Sa Dried composition
DE112018002827T5 (de) 2017-05-30 2020-04-09 Glaxosmithkline Biologicals S.A. Neue Verfahren zur Herstellung eines Adjuvans
JP2021504424A (ja) 2017-12-01 2021-02-15 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム サポニン精製
MX2021012524A (es) 2019-04-12 2021-11-12 C4 Therapeutics Inc Degradadores triciclicos de ikaros y aiolos.
US20220235095A1 (en) 2019-06-05 2022-07-28 Glaxosmithkline Biologicals Sa Saponin purification
CN115073612B (zh) * 2022-06-22 2024-09-27 宁夏大学 一种结核分枝杆菌Zera-71cA蛋白纳米颗粒、制备方法及其用途
GB202318595D0 (en) * 2023-12-05 2024-01-17 Sec Dep For Environment Food And Rural Affairs Acting Through Animal And Plant Health Agency Diagnostic proteins and reagents

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6613881B1 (en) * 1997-05-20 2003-09-02 Corixa Corporation Compounds for immunotherapy and diagnosis of tuberculosis and methods of their use
IL138809A0 (en) * 1998-04-07 2001-10-31 Corixa Corp Fusion proteins of mycobacterium tuberculosis antigens and pharmaceutical compositions containing the same
AU2001241738A1 (en) * 2000-02-25 2001-09-03 Corixa Corporation Compounds and methods for diagnosis and immunotherapy of tuberculosis
WO2001098460A2 (en) * 2000-06-20 2001-12-27 Corixa Corporation Fusion proteins of mycobacterium tuberculosis
CZ20031866A3 (cs) * 2001-01-08 2004-03-17 Isis Innovation Limited Způsob pro stanovení účinnosti léčení mykobakteriální infekce
US20040121322A9 (en) * 2001-02-22 2004-06-24 Cole Stewart T. Comparative mycobacterial genomics as a tool for identifying targets for the diagnosis, prophylaxis or treatment of mycobacterioses
US20030236393A1 (en) * 2002-03-22 2003-12-25 United States Of America Dept Of Vetrans Affairs Virulence genes of M. marinum and M. tuberculosis
US7678379B2 (en) * 2004-06-17 2010-03-16 Beckman Coulter, Inc. Mycobacterium tuberculosis epitopes and methods of use thereof
SI2426141T1 (sl) 2005-04-29 2015-01-30 Glaxosmithkline Biologicals S.A. Postopek za preprečevanje ali zdravljenje infekcije z M tuberculosis
KR101035053B1 (ko) * 2005-06-23 2011-05-19 스태튼스 세룸 인스티튜트 감염 잠복기 동안 발현되는 항원을 포함하는 결핵 백신
WO2008007942A1 (en) * 2006-07-10 2008-01-17 Het Nederlands Kanker Instituut Means and methods for manipulating sequential phagolysomal-cytosolic translocation of mycobacteria, and uses thereof
EP2087128A4 (en) * 2006-11-01 2009-11-04 Immport Therapeutics Inc COMPOSITIONS AND METHODS FOR IMMUNOMINANT ANTIGENES
DK2421557T3 (en) * 2009-04-24 2019-03-25 Statens Seruminstitut TB TUBERCULOSE VACCINE FOR PREVENTION PREVENTION
AU2011209399B2 (en) 2010-01-27 2014-04-10 Glaxo Group Limited Modified tuberculosis antigens

Similar Documents

Publication Publication Date Title
JP2011528896A5 (enExample)
JP2011528895A5 (enExample)
JP2011528897A5 (enExample)
JP2012126742A5 (enExample)
JP2012136541A5 (enExample)
JP2013231081A5 (enExample)
JP2014051497A5 (enExample)
HRP20161458T1 (hr) Polipeptidi, polinukleotidi i pripravci namijenjeni upotrebi u liječenju latentne tuberkuloze
JP2008508859A5 (enExample)
JP2015096557A5 (enExample)
CA2818990C (en) Designed repeat proteins binding to serum albumin
JP2012115277A5 (enExample)
FI3581650T3 (fi) IX-tekijän polypeptidimutantti, sen käyttöjä ja menetelmä sen valmistamiseksi
JP2015517489A5 (enExample)
JP2018520997A5 (enExample)
JP2016056206A5 (enExample)
JP2015510393A5 (enExample)
JP2010512795A5 (enExample)
JP2008536483A5 (enExample)
JP2013507439A5 (enExample)
JP2011136997A5 (enExample)
JP2008529558A5 (enExample)
NZ608502A (en) Polypeptides that bind to human complement component c5
IL187321A (en) Molecules that have a specific link to a surrogate cell that encode monoclonal antibodies capable of neutralizing viruses, medicinal preparations containing them, and their uses in drug preparation
JP2011511805A5 (enExample)